GleamWall
中文EN

NVNO enVVeno Medical Corp

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1661053 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY29.2%
TTM EPS YoY67.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-67.1%
ROA-60.0%
ROIC (approx.)-61.4%
Asset turnover—

Leverage & solvency

Liabilities / assets13.3%
Debt / equity0.00x
Current ratio7.35x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.86x
Accruals ratio-8.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$2.88M$2.08M$2.11M$1.95M$2.58M$2.89M$2.56M$3.51M
SG&A expense$1.66M$1.72M$1.95M$2.06M$2.30M$4.16M$2.40M$3.19M
Operating income-$4.53M-$3.80M-$4.06M-$4.01M-$4.88M-$7.05M-$4.95M-$6.70M
Net income-$4.37M-$3.60M-$3.85M-$3.74M-$4.54M-$6.69M-$4.50M-$6.23M
EBITDA——-$4.03M-$3.98M-$4.85M-$7.01M-$4.91M-$6.66M
EPS (basic)-6.29-5.37-5.89—-7.89-11.52-7.75—
EPS (diluted)-6.29-5.37-5.89—-7.89-11.52-7.75—
Weighted avg. shares (diluted)694,000671,000654,000—575,000581,000581,000—
Balance sheet
Cash & equivalents$2.58M$2.84M$2.60M$3.06M$1.54M$2.04M$2.94M$1.75M
Short-term investments$15.89M$18.64M$22.33M$25.15M$29.41M$33.10M$36.00M$41.40M
Current assets$19.02M$22.08M$25.49M$28.83M$31.50M$35.60M$39.48M$43.73M
PP&E, net$62,000$78,000$16,000$51,000$82,000$113,000$142,000$182,000
Total assets$19.49M$22.66M$26.10M$29.56M$32.35M$36.58M$40.58M$44.95M
Current liabilities$2.59M$1.89M$2.14M$2.12M$2.40M$3.02M$1.66M$2.10M
Total liabilities$2.59M$1.99M$2.35M$2.43M$2.90M$3.52M$2.27M$2.79M
Shareholders' equity$16.90M$20.67M$23.75M$27.13M$29.45M$33.06M$38.31M$42.16M
Shares outstanding695,000673,000656,000656,00020.22M19.25M17.54M501,000
Cash flow statement
Operating cash flow-$3.18M-$3.55M-$3.24M-$3.44M-$4.39M-$3.71M-$4.02M-$5.11M
Capital expenditure———$0$0——$4,000
Free cash flow———-$3.44M-$4.39M——-$5.11M
Investing cash flow$2.73M$3.67M$2.77M$4.18M$3.65M$2.82M$5.20M-$11.06M
Financing cash flow$187,000——$782,000———$0
Depreciation & amortization——$31,000$31,000$31,000$34,000$40,000$40,000
Stock-based compensation$410,000$397,000$467,000$637,000$688,000$1.44M$651,000$1.02M

Free plan shows the latest 8 periods; Pro shows all 38 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.